Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics-Reference-Cited by-同舟云学术

Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics

Published:2016-03-03 Issue:3 Volume:11 Page:e0147381
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Willenbacher Ella,Weger Roman,Rochau Ursula,Siebert Uwe,Willenbacher Wolfgang,

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference20 articles.

1. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients;SK Kumar;Leukemia,2014

2. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study;SK Kumar;Leukemia,2012

3. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial;J San Miguel;The Lancet Oncol,2013

4. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG);EM Ocio;Leukemia,2014

5. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma;DS Siegel;Blood,2012

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The establishment of a multiple myeloma clinical registry in the Asia–Pacific region: The Asia–Pacific Myeloma and Related Diseases Registry (APAC MRDR);BMC Medical Research Methodology;2024-05-02

2. Case report: pomalidomide as maintenance after salvage autologous stem cell transplantation in a patient with relapsed multiple myeloma;Oncohematology;2023-12-07

3. Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma;Frontiers in Oncology;2023-11-02

4. Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma;Future Oncology;2022-06

5. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial;Blood Cancer Journal;2022-01-24